DXCM
DEXCOM INC
- PER (TTM)
- 26.01
- PER (Forward)
- 19.85
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 7.91
- 시가총액
- 23.39B
- 배당수익률
- -
- 베타
- 1.40
- 1개월 수익률
- -7.72%
- 3개월 수익률
- -13.38%
- 6개월 수익률
- 2.24%
- 1년 수익률
- -27.28%
- 2년 수익률
- -
- 5일 평균거래량
- 5244960
- 60일 평균거래량
- 4542525
- 1년 평균거래량
- 4858396
- 5d/60d 거래량 비율
- 1.15×
- 60d/1y 거래량 비율
- 0.93×
- 변동성(60일, 연환산)
- 35.93%
- BB 스퀴즈 스코어
- 0.82
- SMA50 비율
- 0.94
- SMA200 비율
- 0.88
- RSI (14)
- 45
- 20일 수렴도
- 0.03
- 52주 최고
- 89.53
- 52주 최저
- 54.84
- 고점 대비
- -32.30%
- 저점 대비
- 10.52%
펀더멘털 갱신: 2026-05-10T08:41:29+00:00 · 시세 갱신: 2026-05-10T06:28:33+00:00
회사 정보
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.